Recent Research Funding

Tom Russo and Tim Umland.

More than $2 million in annual extramural funding goes to researchers in our division, including Thomas Russo, MD, (left), shown with collaborator Timothy C. Umland, PhD.

Faculty research is supported by extramural funding of more than $2 million annually. The majority of support is derived from national funding agencies such the National Institutes of Health, the Department of Defense and the Veterans Administration.

  • Clinical and Translational Science Award: Buffalo Clinical and Translational Research Center. Timothy Murphy (Principal Investigator). National Center for Advancing Translational Sciences. $19,101,902. 8/1/2019-12/1/2024.
  • Genome Evolution During Bacterial Persistence in the Human Airways in COPD. Timothy Murphy (Principal Investigator). NIAID. $2,653,298. 7/1/2019-6/1/2024.
  • Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannii. Thomas Russo (Principal Investigator). Veterans Administration. $699,244. 10/1/2019-9/1/2023.
  • Igniting Hope: Mobilizing Community Resources to Achieve Health Equity. Timothy Murphy (Principal Investigator). NCATS. $24,711. 7/1/2020-6/1/2023.
  • Mab Passive Vaccination against Acinetobacter baumannii. Thomas Russo (Co-Investigator). NIH. $491,635. 9/1/2017-8/1/2022.
  • Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae. Thomas Russo (Principal Investigator). NIH. $431,682. 8/1/2020-7/1/2022.
  • DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumannii. Thomas Russo (Co-Principal Investigator). NIH/NIAID. $981,697. 8/1/2018-8/1/2021.
  • Training the Next Generation of Physician Scientists T35 Training Grant. Timothy Murphy (Principal Investigator). NIAID. $242,416. 9/1/2016-6/1/2021.
  • SOS Response as a Generator of Antibiotic Resistance and Role of Zinc as SOS Inhibitor. John Crane (Principal Investigator). National Institutes of Health. $444,325. 6/1/2019-5/1/2021.
  • National Center for Advancing Translational Sciences. Timothy Murphy (Principal Investigator). NIH. 9/1/2015-6/1/2020.
  • A CRISPR-based platform for testing neutrophil responses in the ovarian cancer microenvironment (3R01CA188900-05W1). Brahm Segal (Principal Investigator). NCI. $207,918. 8/1/2019-5/1/2020.
  • Novel Immunological Biomarkers in Ovarian Cancer Prognosis. Brahm Segal (Principal Investigator). NIH. $3,148,229. 6/1/2015-5/1/2020.
  • Development of a HTP Assay for Inhibitors of Aerobactin Production. Thomas Russo (Co-Investigator). NIH. $358,875. 2/1/2016-1/1/2020.
  • The Mae Stone Goode Charitable Trust. Thomas Cimato (Principal Investigator), Brahm Segal (Co-Principal Investigator). $100,000. 3/1/2016-3/1/2019.
  • Development of a diagnostic test for hypervirulent Klebsiella pneumoniae. Thomas Russo (Principal Investigator). NIH. $438,625. 3/1/2016-2/1/2019.
  • Development of HTP Assay for Inhibitors of Aerobactin Production(R01AI116998). Andrew Gulick (Principal Investigator), Thomas Russo (Co-Investigator). National Institutes of Health. 2/1/2016-1/1/2019.